In this study, we aimed to confirm previously reported differences in imaging biomarkers between the different APOE ε4 populations and to evaluate the associations of the aforementioned imaging and blood biomarkers in a cohort comprised of cognitively unimpaired individuals with varying APOE ε4-related genetic risk for sporadic AD. This evidence concerns the gene APOE and Alzheimer disease.